전립선비대증에서 대사증후군 관련요인 분석 = The Relating Factors of Metabolic Syndrome to Benign Prostatic Hyperplasia

다국어 초록 (Multilingual Abstract)

Purpose: Benign prostatic hyperplasia(BPH) is a representative urological disease in men at senescence. The etiology of BPH is multifactorial, with chronic conditions, such as non insulin dependent diabetes mellitus (NIDDM), treated hypertension, obesity, low and high density lipoprotein (HDL) cholesterol levels and high insulin levels, constitute for the development of BPH. The prevalence of metabolic syndrome in a BPH population was investigated and the relationship between BPH and metabolic syndrome evaluated.
Materials and Methods: The BPH group consisted of 162 patients(63.4±7.8 years old) diagnosed as BPH and the control group of 68 patients(59.7±6.4 years old) without voiding difficulties. In each group, the relating factors, prevalence of BPH and metabolic syndrome were investigated and analyzed for comparison.
Results: Comparing the voiding factors of the BPH and control groups, all of the measured values showed aggravation of the voiding difficulty in the BPH compared with the control group. The prevalence of metabolic syndrome in the BPH group was 64.2%, which was about double that in the control group(32.4%)(p＜0.001). Among the components of metabolic syndrome, hypertension(70.4%) was found to have the highest prevalence.
Conclusions: The probability of patients with BPH having metabolic syndrome is high compared to those without BPH. Consequently, in BPH patients, careful evaluation for metabolic syndrome is needed, with the early diagnosis and proper management of metabolic syndrome should accompany the treatment of BPH.

참고문헌 (Reference)

1 "and lipid metabolism in doxazosin- treated patients with hypertension. Am J Hypertens 1992" 827-31,

2 "The metabolic syndrome" 29 : 36-43, 2004

3 "Relation between benign prostatic hyperplasia and obesity and estrogen" 52 : 291-294, 2004

4 "Reaven GM. Effect of prazosin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension. Am J Med 1989" 14-8,

5 "Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988" 1595-607,

6 "Prediction of coronary heart disease using risk factor categories" 97 : 1837-1847, 1998

7 "Physiopathology of BPH obstruction" 67 : 13-16, 1995

8 "Pearson TA. 27th Bethesda conference. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 1996" 27 : 957-1047, 1996

9 "Mehnert H. New aspects of insulin resistance in hypertension. Eur Heart J 1994" 78-81,

10 "McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 1990" 477-86,

11 "Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991" 469-71,

12 "Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia" 39 : 151-158, 2001

13 "Horton R. Altered metabolism of androgens in elderly men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1977" 695-701,

14 "Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004" 172 : 1390-1393, 2004

15 "Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM" 173-94,

16 "Fagius J. The sympathetic outflow in vasoconstrictor nerve fascicles to muscle is increased during euglycacemic hyperinsulinemia. Diabetologia 1989"

17 "Executive summary of the third report of the national cholesterol education program expert panel on detection and treatment of high blood cholesterol in adults" 285 : 2486-2497, 2001

18 "Eckhardt MD. Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep 2001" 2 : 297-301, 2001

19 "Cosgrove M. Altered blood androgens in elderly men with prostate hyperplasia. J Clin Endocrinol Metab 1975" 793-6,

20 "Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia" 1 : 157-162, 1998

21 "Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia." Blood Press 8 : 29-36, 1999

22 "Cho BL. Prevalence and risk factors of the metabolic syndrome as defined by NCEP-ATPIII. J Korean Acad Fam Med 2003" 24 : 135-143, 2003

23 "Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988" 415-20,

24 "Belanger A. Comparative study of plasma steroid and steroid glucuronide levels in normal men and in men with benign prostatic hyperplasia. Prostate 1987" 33-40,